Differences in the Eradication of Helicobacter Pylori by Different Therapies
NCT ID: NCT05097846
Last Updated: 2022-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2021-06-17
2022-10-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vonoprazan Fumarate in Combination With Amoxicillin for the First-line Eradication of Helicobacter Pylori -- a Multicenter, Randomized, Parallel Controlled Study
NCT05196945
A Study of Vonoprazan in Adults With Helicobacter Pylori
NCT04753437
Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT06168084
Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
NCT05726734
Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection
NCT05719831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1: Vonoprazan Fumarate + amoxicillin + doxycycline
Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
Vonoprazan Fumarate + amoxicillin + doxycycline
Group2: Vonoprazan Fumarate + furazolidone + doxycycline
Group2 Vonoprazan Fumarate + furazolidone + doxycycline
Vonoprazan Fumarate + furazolidone + doxycycline
Group3: esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Group4: esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group1 Vonoprazan Fumarate + amoxicillin + doxycycline
Vonoprazan Fumarate + amoxicillin + doxycycline
Group2 Vonoprazan Fumarate + furazolidone + doxycycline
Vonoprazan Fumarate + furazolidone + doxycycline
Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Urea breath test (UBT) was positive for Hp infection;
3. WIthout any anti-Hp treatment before
4. Endoscopy was performed within 1 month
5. Understanding the purpose and procedure of the study, voluntarily participating in the study and signing a written informed consent.
Exclusion Criteria
2. Using PPI, histamine H2 receptor antagonist, antibiotics, bismuth, probiotics or drugs with antibacterial effects within 4 weeks before treatment.
3. Using adrenal corticosteroids, non-steroidal anti-inflammatory drugs and anticoagulants
4. The disease or clinical condition that may interfere with the treatment evaluation of the study, such as liver disease, cardiovascular disease, lung disease, kidney disease, metabolic disease, psychiatric disease, or malignant tumor
5. Pregnant or lactating women
6. Participated in other clinical studies within 3 months prior to the registration of this clinical study
7. Suspected history of antibiotic abuse
8. Patients with craniocerebral injury, mental illness or epilepsy who cannot communicate with others or other diseases that may affect follow-up
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
wang xiaoyan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
wang xiaoyan
Director, Head of Gastroenterology, Principal Investigator, Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The third Xiangya Hospital of central south University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang Z, Liu F, Ai F, Chen X, Liu R, Zhang C, Fang N, Fu T, Wang X, Tang A. The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori. Front Pharmacol. 2023 May 5;14:1143969. doi: 10.3389/fphar.2023.1143969. eCollection 2023.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.